If these were normal circumstances, Yuki Bhambri would probably be back on the grind of the tennis tour trying to qualify for a Grand Slam again. It would be a far cry from his breakthrough 2018 season, where he crossed top 100 and played all four Majors, but at least he would be back and fighting on court.
However as things stand, the former India No 1 has not played a competitive match since October 2018 after battling a debilitating knee injury that wasnt correctly diagnosed for months and led to a layoff that is 18 months and counting now.
From a career-best ranking of 83 in April 2018 to losing his ranking and being tagged as inactive on the official ATP charts, it has been a period of difficulty and confusion for the 27-year-old, who has been a junior world No 1 and Grand Slam champion.
Its been a pain a struggle. The [past] 18 months have felt like five years. From not being able to really put any load on my knee, I think its a big achievement to be able to finally get back to playing tennis and do even the basic exercises, Bhambri told Scroll.in.
But even then, there are two ways to look at the long time away from the sport due to injury and now an extended break due to the coronavirus pandemic. The positive is, of course, a shutdown of the entire tennis tour means that the timeline for recovery is extended. Does he see this time off, although due to a negative reason, as beneficial?
Yes, it does for me and for everyone whos been out injured because you dont miss out on the tour. Everyone in the same situation, everyone comes back without hitting a tennis ball for months. Ill not be missing the Grand Slams or any events and it gives me time to come back. So for the few ones, like me, Roger Federer, Juan Martin del Potro, this is a good time. Of course, you dont want it to happen due to a pandemic, he added.
The Indian has been spending time at home in Delhi, trying to get whatever fitness training he can at home with the tennis courts shut amid the nationwide lockdown but he knows its not enough.
Its difficult and different, no matter how much you train at home, its not the same. Youre obviously doing it for your career, for tennis and Im not able to play it and theres only a certain amount that you can really do at home. For me, its really just about being active and doing bits and pieces so that I dont have to start from scratch when I get back on the court, he added.
I was already following a bunch of exercises I need to for my knee rehab. But sometimes modifications are needed and Im in constant touch with my team. Theres only so much you know you can do but I think Ive been good enough in being active, said the Indian who is coached by Stephen Koon from the Impact Tennis Academy in Thailand.
Bhambri admitted that he is unsure if he would be a 100% if the tour were to restart.
Its pretty good but I am not match-fit. I made a lot of progress and if I had to, even right now Id give myself a 70% chance. I need to get out there and practice because I havent done anything in regards to my physical fitness for about over a year and a half now.
The body takes some time to get used to it again and for that Id have to be on the court I presume for at least a couple of months, to be able to get back to running and being able to take the load of a match. I had just started to do that and get into a routine when the lockdown happened. Once its over Ill get back to practice but looking at things, we may not have a tennis season this year he added.
As candid as Bhambri is while talking about the past few months, the toll becomes evident when he describes the excruciating details of his injury and the experimental treatment. He was injured in mid-2018 but it was only in September 2019 when he consulted with Dr Angel Ruiz Cortorro, who has worked with many top injured tennis players including Rafael Nadal, that Bhambri got a clear idea of the problem.
From what I understand of the diagnosis I have a small, partial tear in the medial part of my knee. Because it was tiny and in the middle of the tendon, no one could really figure it out and I was somewhere stuck in between because surgery would have been too big a step to repair it and the basic modern medication and therapy werent working. So I had to try different kinds of treatments, different injections to help heal the tendon, he said.
I was seeing doctors in the US and getting different opinions. But a few of them had the same idea, which was an experimental treatment called stem cell. This procedure was more advanced in Spain and there are very few countries that actually do it; they dont even do it in the States. Since I was getting different opinions, I decided to get in touch with Dr Cortorro just to have another opinion and went with him because hes the one who has treated a lot of tennis players who had knee trouble, Bhambri added.
The decision paid off because after almost a year of taking different injections and waiting for months to see if they made a difference, he finally made progress in late 2019. Around the new year is when I got back on court to hit the ball and I have seen improvement every week, which is a good sign.
Also read: Yuki Bhambri on building up the ammo to fire his way to the top
In his career so far, Bhambri is no stranger to injuries or fighting back from them, but even then one needs immense self-belief to be able to deal with this long and complicated rehab process.
There havent been too many positives, he laughed, but admitted that his success in 2017-18 was a reminder of what he is capable of.
I needed to keep reminding myself that I want to come back and continue playing to get back at the level I was at. I think having tasted success of finally playing the Slams, my first Wimbledon, winning a few matches at the Masters 1000 in Indian Wells and Miami, pushed me as well to try. Wanting to play those events again kept me going, he said.
Coming from a family of tennis players also helped the 27-year-old. His sister Ankita is the Indian Fed Cup coach while other sister Sanaa and cousin Prerna are all pro tennis players.
Theyre always on the lookout, helping out; specially both my sisters who have been helping with the research, making sure I am finishing training and not being lazy my parents coming in and asking if Ive iced my knee or not. So theyve all been actively involved and try to help it in whatever way they can, he said.
Read the original:
Indian tennis: For injury-plagued Yuki Bhambri, the lockdown is both a chance and another challenge - Scroll.in
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020